Subcutaneous Orencia Seen to Alleviate Polyarticular-course JIA Symptoms in Phase 3 Trial
News
Abatacept, marketed as Orencia by Bristol-Myers Squibb, was seen to improve the symptoms of polyarticular-course juvenile idiopathic arthritis (pJIA) in a Phase 3 clinical trial. Additionally, subcutaneous administration of Orencia was ... Read more